Cargando…
FLLL32, a curcumin analog, ameliorates intestinal injury in necrotizing enterocolitis
BACKGROUND: Necrotizing enterocolitis (NEC) is a devastating gastrointestinal disease that primarily affects premature infants. It is characterized by inflammation and leukocyte infiltration that can progress to intestinal necrosis, perforation, systemic inflammatory response, and death. In this stu...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476581/ https://www.ncbi.nlm.nih.gov/pubmed/28652797 http://dx.doi.org/10.2147/JIR.S131051 |
_version_ | 1783244614655803392 |
---|---|
author | Eckert, Jeffrey Scott, Brian Lawrence, Shelley M Ihnat, Michael Chaaban, Hala |
author_facet | Eckert, Jeffrey Scott, Brian Lawrence, Shelley M Ihnat, Michael Chaaban, Hala |
author_sort | Eckert, Jeffrey |
collection | PubMed |
description | BACKGROUND: Necrotizing enterocolitis (NEC) is a devastating gastrointestinal disease that primarily affects premature infants. It is characterized by inflammation and leukocyte infiltration that can progress to intestinal necrosis, perforation, systemic inflammatory response, and death. In this study, we examined the effect of FLLL32, a curcumin analog, on an NEC-like neonatal intestinal injury model. METHODS: NEC was induced in CD-1 mice pups using the Paneth cell ablation and Klebsiella infection model. Pups were divided into sham, NEC, and NEC + FLLL32 groups. At the end of the experiment, pups were euthanized; whole blood and small intestines were harvested. Intestinal inflammatory cytokine profile, in vivo intestinal permeability using serum fluorescein isothiocyanate-dextran, and histological injury scores were compared between the groups. RESULTS AND CONCLUSION: FLLL32-treated pups had lower intestinal injury, improved intestinal permeability, and lower proinflammatory cytokine profiles compared to those in untreated pups with NEC. These results suggest that FLLL32 plays a protective role in NEC. |
format | Online Article Text |
id | pubmed-5476581 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-54765812017-06-26 FLLL32, a curcumin analog, ameliorates intestinal injury in necrotizing enterocolitis Eckert, Jeffrey Scott, Brian Lawrence, Shelley M Ihnat, Michael Chaaban, Hala J Inflamm Res Original Research BACKGROUND: Necrotizing enterocolitis (NEC) is a devastating gastrointestinal disease that primarily affects premature infants. It is characterized by inflammation and leukocyte infiltration that can progress to intestinal necrosis, perforation, systemic inflammatory response, and death. In this study, we examined the effect of FLLL32, a curcumin analog, on an NEC-like neonatal intestinal injury model. METHODS: NEC was induced in CD-1 mice pups using the Paneth cell ablation and Klebsiella infection model. Pups were divided into sham, NEC, and NEC + FLLL32 groups. At the end of the experiment, pups were euthanized; whole blood and small intestines were harvested. Intestinal inflammatory cytokine profile, in vivo intestinal permeability using serum fluorescein isothiocyanate-dextran, and histological injury scores were compared between the groups. RESULTS AND CONCLUSION: FLLL32-treated pups had lower intestinal injury, improved intestinal permeability, and lower proinflammatory cytokine profiles compared to those in untreated pups with NEC. These results suggest that FLLL32 plays a protective role in NEC. Dove Medical Press 2017-06-14 /pmc/articles/PMC5476581/ /pubmed/28652797 http://dx.doi.org/10.2147/JIR.S131051 Text en © 2017 Eckert et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Eckert, Jeffrey Scott, Brian Lawrence, Shelley M Ihnat, Michael Chaaban, Hala FLLL32, a curcumin analog, ameliorates intestinal injury in necrotizing enterocolitis |
title | FLLL32, a curcumin analog, ameliorates intestinal injury in necrotizing enterocolitis |
title_full | FLLL32, a curcumin analog, ameliorates intestinal injury in necrotizing enterocolitis |
title_fullStr | FLLL32, a curcumin analog, ameliorates intestinal injury in necrotizing enterocolitis |
title_full_unstemmed | FLLL32, a curcumin analog, ameliorates intestinal injury in necrotizing enterocolitis |
title_short | FLLL32, a curcumin analog, ameliorates intestinal injury in necrotizing enterocolitis |
title_sort | flll32, a curcumin analog, ameliorates intestinal injury in necrotizing enterocolitis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476581/ https://www.ncbi.nlm.nih.gov/pubmed/28652797 http://dx.doi.org/10.2147/JIR.S131051 |
work_keys_str_mv | AT eckertjeffrey flll32acurcuminanalogamelioratesintestinalinjuryinnecrotizingenterocolitis AT scottbrian flll32acurcuminanalogamelioratesintestinalinjuryinnecrotizingenterocolitis AT lawrenceshelleym flll32acurcuminanalogamelioratesintestinalinjuryinnecrotizingenterocolitis AT ihnatmichael flll32acurcuminanalogamelioratesintestinalinjuryinnecrotizingenterocolitis AT chaabanhala flll32acurcuminanalogamelioratesintestinalinjuryinnecrotizingenterocolitis |